Theraputic Plasmapheresis in Neurological Disorders, Baghdad/Iraq
American Journal of Internal Medicine
Volume 4, Issue 6, November 2016, Pages: 120-123
Received: Oct. 26, 2016; Accepted: Nov. 10, 2016; Published: Dec. 16, 2016
Views 2607      Downloads 78
Authors
Basim Hanoon Jabar, Neurology Department, Neurosciences Teaching Hospital, Baghdad, Iraq
Bahaa A. Hassan, Neurology Department, Neurosciences Teaching Hospital, Baghdad, Iraq
Article Tools
Follow on us
Abstract
Background: plasma exchange (PE) involves the separation and removal of plasma from corpuscular blood and the replacement of it with various fluids, while plasmapheresis only refers to the removal of plasma. AIM OF STUDY: To study our experience with PE in our 487 patients of different neurological disorders, determined most referring diseases. Materials and Methods: Retrospective study of PE procedures done during a period of 36 months, from January 2013to January 2016 in a neurosciences hospital in Baghdad/Iraq. Data analysis is used SPSS 20. Results: The main indication for PE was CIDP (339 patients; 69.20%). Age of patients ranged from 8-85 (mean = 46.22 years). Up to our knowledge is largeset number of patients used in that period, no mortality found. Conclusion: The analysis of 487 cases of PE done in our department shows that PF is usually well tolerated. Possible adverse reactions mainly relate to vascular access.
Keywords
Chronic Inflammatory Demylinating Polyneuropathy, Plasmapheresis, Therapeutic Plasma Exchange
To cite this article
Basim Hanoon Jabar, Bahaa A. Hassan, Theraputic Plasmapheresis in Neurological Disorders, Baghdad/Iraq, American Journal of Internal Medicine. Vol. 4, No. 6, 2016, pp. 120-123. doi: 10.11648/j.ajim.20160406.16
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Selective Plasma Component Removal: Alternatives to Plasma Exchange. Alvaro A. Pineda and, Howard F. Taswell, Version of Record online: 12 NOV 2008.
[2]
V. Abdul Gafoor, James Jose, K. Saifudheen. Plasmapheresis in neurological disorders: Experience from a tertiary care hospital in South India. Ann Indian Acad Neurol. 2015 Jan-Mar;18(1):15–19. [PubMed].
[3]
Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, et al. Therapeutic plasma exchange: An update from the Canadian Apheresis Group. Ann Intern Med. 1999;131:453–62. [PubMed].
[4]
The use of therapeutic plasmapheresis for neurological disorders. National Institutes of Consensus Development Conference.Transfus Med Rev. 1998; 2:48–53. [PubMed].
[5]
Weinstein R. Therapeutic apheresis in neurological disorders. J ClinApher.2000;15:74–128. [PubMed].
[6]
Alexandra Schröder, Ralf A Linker & Ralf Gold. Review Plasmapheresis for neurological disorders. Expert Review of Neurotherapeutics: Volume 9, Issue 9, 2009.
[7]
Bouget J, Chevret S, Chastang C, Raphael JC. Plasma exchange morbidity in GBS: Results from the French prospective, randomised, multicentre study. French Cooperative Group. Crit Care Med. 1993;21:651–8. [PubMed].
[8]
Hartung HP, Willison HJ, Keiseier BC. Acute immuneinflammatory neuropathy: Update on Guillain-Barre syndrome. CurrOpin Neurol. 2002;15:571–7. [PubMed].
[9]
Van der Meche FG, Schmitz PI. A randomised trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barre Syndrome. Dutch Guillain Barre Study Group. N Engl J Med. 1992;326:1123–9. [PubMed].
[10]
Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology.2011; 76: 294–300. [PMC free article][PubMed].
[11]
Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG, Demyelinating neuropathy in diabetes mellitus. Arch Neurol. 2002 May; 59(5):758-65.
[12]
Wong EC, Balogun RA. Therapeutic apheresis in pediatrics: Technique adjustments, indications and nonindications, a plasma exchange focus. J ClinApher. 2012;27:132–7. [PubMed].
[13]
Basic-Jukic N, Brunetta B, Kes P. Plasma exchange in elderly patients. TherApher Dial.2010;14:161–5. [PubMed].
[14]
Korach JM, Berger P, Giraud C, Le Perff-Desman C, Chillet P. Role of replacement fluids in the immediate complications of plasma exchange. French Registry Cooperative Group. Intensive Care Med. 1998;24:452–8. [PubMed].
[15]
Stegmayr B, Ptak J, Wikstrom B, Berlin G, Axelsson CG, Griskevicius A, et al. World apheresis registry 2003-2007 data. TransfusApher Sci. 2008;39:247–54. [PubMed].
[16]
Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: A prospective study of 1,727 procedures. J ClinApher.2007;22:270–6. [PubMed].
[17]
Sharma RR, Saluja K, Jain A, Dhawan HK, Thakral B, Marwaha N. Scope and application of therapeutic apheresis: Experience from a tertiary care hospital in North India. TransfusApher Sci. 2011;45:239–45. [PubMed].
[18]
Ward DM. Conventional apheresis therapies: A review. J ClinApher.2011;26:230–8. [PubMed].
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186